Searchable abstracts of presentations at key conferences in endocrinology

ea0019s75 | The ‘how to’ guide on scientific communication | SFEBES2009

Poster presentations: from poster layout to data presentation

Lavery GG

Clear communication of your work to the scientific community is vital, and the poster is a popular format for achieving this. Presenting posters is something that scientists do throughout their career, but may never maximize the benefits they can bring, so knowing what makes a good poster presentation is an important skill to attain. The ultimate goal is to attract an interested scientist (or reviewer), provide them with the means to view, understand and appreciate your work, ...

ea0019p135 | Diabetes, Metabolism and Cardiovascular | SFEBES2009

Knockdown of H6PDH in C2C12 muscle cells impairs 11β-HSD1 activity and myogenic differentiation

Saqib KM , Sherlock M , Walker EA , Stewart PM , Lavery GG

NADPH generated by hexose-6-phosphate dehydrogenase (H6PDH) within the lumen of the endoplasmic reticulum (ER) drives the reductase activity of 11β-hydroxysteroid dehydrogenase type 1 (11-βHSD1) allowing the production of active glucocorticoids. H6PDH knockout (H6PDHKO) mice develop a vacuolating myopathy, reduced muscle mass and display activation of the ER stress response. However, the role of glucocorticoids and 11β-HSD1 in the myopathy phenotype is not clear...

ea0011p307 | Diabetes, metabolism and cardiovascular | ECE2006

Altered cholesterol and bile acid homeostasis in the hexose-6-phosphate dehydrogenase (H6PDH) knockout mouse

Hewitt KN , Bujalska IJ , Lavery GG , Stewart PM , Walker EA

In humans, glucocorticoids (GC) are implicated in the pathogenesis of obesity and insulin resistance. GCs are regulated at the prereceptor level by 11beta-hydroxysteroid dehydrogenases (11β-HSD). 11β-HSD type 1 (11β-HSD1) predominantly displays oxo-reductase activity, converting cortisone in man, 11-dehydrocorticosterone in rodents, to cortisol and corticosterone respectively – a reaction requiring the cofactor NADPH. The generation of a hexose-6-phosphate ...

ea0012s16 | New frontiers in steroid hormone metabolism | SFE2006

Hexose-6-phosphate dehydrogenase and glucocorticoid metabolism

Lavery GG , Chalder SM , Bujalska I , Parker KL , White PC , Stewart PM , Walker EA

Glucocorticoid (GC) hormone action can be modulated at the pre-receptor level by the endoluminal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1). 11βHSD1 is a bidirectional enzyme that primarily acts as an oxo-reductase in vivo, converting the pro-hormone cortisone to its active form cortisol, while its dehydrogenase activity results in inactivation of cortisol to cortisone. 11βHSD1 oxo-reductase activity allows GC reactivation in a tissue s...

ea0019oc5 | Young Endocrinologist prize session | SFEBES2009

Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves insulin sensitivity in skeletal muscle through modulation of IRS1 serine phosphorylation

Morgan SA , Gathercole LL , Lavery GG , Sherlock M , Bujalska IJ , Sethi JK , Hegyi K , Stewart PM , Smith DM , Tomlinson JW

Glucocorticoid (GC) excess is characterized by increased adiposity, skeletal myopathy and insulin resistance. Despite increasing use of GCs as therapeutic agents, the precise molecular mechanisms that underpin GC-induced insulin resistance are unknown. Within skeletal muscle, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts cortisone (11-dehydrocorticosterone in rodents) to the active GC, cortisol (corticosterone in rodents) and thus amplifies local GC act...